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with 1 x 105 donor dendritic cells 60 days after transplantation. These results demonstrate an important in vivo role for donor dendritic cells in the stimulation of allograft rejection.
Rejection of mouse islet allografts is prevented when donor histoincompatible islets are treated with anti-Ia antiserum and complement prior to transplantation (1) . Because the islet cells are la- (2) , the antiserum treatment presumably eliminates Ia+ donor lymphoid cells. As proposed previously, these passenger lymphocytes may be the donor cells responsible for initiating islet graft rejection (1, 3) .
Previous studies have suggested that the principal type of passenger leukocyte is the dendritic cell (4) (5) (6) . Dendritic cells are bone marrow-derived (7) Ia' cells (8, 9 ) that express a specific antigen identified with a monoclonal antibody 33D1 (10) but lack the characteristic markers of other leukocytes such as F4/80 and Mac-1 (macrophages), surface Ig (B cells), and thy-1, Lyt-1,2 (T cells) (9) (10) (11) . Dendritic cells are active stimulators of lymphocyte responses in culture, particularly the primary mixed lymphocyte response, where they are 100 times more potent than unfractionated spleen cell suspensions (4, 5) . Small numbers of rat lymph dendritic cells can induce the rejection of rat kidney allografts (6) . In all of these studies, dendritic cells have been derived from lymphoid organs or lymph. Dendritic cells have not been identified previously in graft tissue using a cell-specific antibody.
In this study, we demonstrate by immunofluorescence that dendritic cells are present in freshly isolated mouse islets of Langerhans and that these cells can be eliminated with a monoclonal antibody to dendritic cells and complement. Pretreatment of donor mouse islets with anti-dendritic cell antibody plus complement prior to transplantation prevented rejection of mouse islets transplanted across a major histocompatibility barrier. These H-2b) male mice (age, -5-6 weeks) were obtained from The Jackson Laboratory.
B6 transplant recipients were made diabetic by the intravenous injection of streptozotocin (160 mg/kg of body weight). Nonfasting plasma glucose levels were determined three times a week on blood obtained from the orbital sinus of B6 diabetic mice, and only mice with plasma glucose levels of >400 mg/dl for three consecutive bleedings were used as recipients. Rejection was defined as a nonfasting serum glucose of >250 mg/dl for two consecutive bleedings.
Islet Isolation. Islets were isolated by the collagenase technique as described (1) . The isolated islets were separated on a Ficoll gradient (Pharmacia) and hand picked with the aid of a dissecting microscope (12).
Antibodies. The following antibodies were used for immunofluorescence assays: (i) A.TH anti-A.TL, a mouse alloantiserum that is directed against Ik determinants; (ii) A.TL anti-A.TH, a mouse alloantiserum directed against P determinants; (iii) 10-2.16, a mouse monoclonal antibody that is directed against murine I-Ak (13); and (iv) 33D1, a rat monoclonal antibody which is specific for mouse dendritic cells (5, 10) . The 33D1 antibody also was used for the treatment of allogeneic islets prior to transplantation. The A.TH anti-A.TL and A.TL anti-A.TH antisera and the 10-2.16 reagent were produced in the Department of Genetics, Washington University School of Medicine. Cells for production of 10-2.16 were obtained from the Salk Institute (San Diego, CA). The monoclonal reagents were used in the form of culture supernatant.
Fluoresceinated goat anti-mouse IgG (Fl-anti-mouse IgG) was purchased from Tago (Burlingame, CA) and used to localize A.TH anti-A.TL, A.TL anti-A.TH, and 10-2.16 antisera. Biotin-labeled mouse anti-rat immunoglobulin (B-antirat Ig) and fluorescein-avidin (Fl-avidin) (Vector Laboratories, Burlingame, CA) were used for staining with the 33D1 reagent (10).
Rabbit sera (GIBCO) were screened by the microcytotoxicity test (14) in order to select one that lacked toxicity to islets while maintaining a high degree of specific complement activity.
Immunofluorescence. After isolation, islets either were processed immediately or were maintained in tissue culture medium (CMRL 1066) at 37°C in 95% air for 12 hr. The islets Abbreviations: B6, C57BL/6J; B1O.BR, B1O.BR/SgSnJ; Fl-antimouse IgG, fluoresceinated goat anti-mouse IgG; B-anti-rat Ig, biotin-labeled mouse anti-rat immunoglobulin; Fl-avidin, fluoresceinavidin.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Islet Transplantation. Freshly isolated B10.flR islets were incubated with monoclonal anti-dendritic cell reagent for 45 min at room temperature in Hanks' balanced salt solution containing 0.5% bovine serum albumin. The treated islets were washed twice by centrifugation and incubated for 30 min at 370C with rabbit complement. Control islets were transplanted immediately after isolation or were treated with only rabbit complement. Each B6 (H-2b) diabetic recipient received 550-880 treated or untreated B10.BR (H-2k) islets by embolizing the islets into the terminal sinusoids of the liver by injection into the portal vein (15). We have demonstrated previously that islets transplanted as isografts via the portal vein will rapidly reverse the diabetic state to normal and maintain normoglycemia in the recipients for >300 days (1) .
Dendritic Cells for Induction of Rejection. Donor B10.BR dendritic cells were prepared from spleen cell suspensions as described (16) . Sixty-five days after transplantation, normoglycemic B6 mice with stable B10.BR islet transplants were given a single injection of 1 x 105 viable cells enriched for dendritic cells in 0.5 ml of medium via the tail vein.
RESULTS
Identification of Ia' Lymphoid and Dendritic Cells in Isolated Islets. Immunofluorescence studies using alloantiserum recognizing murine Ta determinants revealed two morphologically distinct populations of Ia' cells within B10.BR mouse islets (Fig. 1, group 1) . One population was composed of large cells with finger-like protrusions, spaced between the la-islet cells (Fig. 2) that were similar to the dendritic cells described in lymphoid organs (8) (9) (10) (11) 16 ). These cells were present within the parenchyma of the islets and were rarely observed on the islet surface. A second Ia' popula- A monoclonal anti-I-A antibody also detected both lymnphoid-like and dendritic-like populations of Ia' cells within B10.BR islets (Fig. 1, group 2) , although the intensity of staining and the total number of Ia' cells per islet was decreased in comparison to that observed with the alloanti- (Fig. 1, group 8) .
Treatment of islets with A.TH anti-A.TL antiserum, complement, and DNase reduced the number of dendritic and lymphocytic cells detected by immunofluorescence to background levels (Fig. 1, group 4) .
A monoclonal antibody to mouse dendritic cells (33D1) was used to determine whether the large Ia' cells with elongated processes in the islets were dendritic cells. It is known that the number of determinants detected by 33D1 is very small (about 14,000 antibody binding sites per cell) compared to >200,000 anti-I-A binding sites (9, 10). Therefore, the more sensitive biotin/avidin modification of indirect immunofluorescence was used with 33D1 reagent. This technique produced readily detectable staining of large dendritic cells (Fig. 1, group 3 (Fig. 1, group 5) . As expected, removal of Ia' cells eliminated 33D1+ cells (Fig. 1, group 6) . The Ia' lymphocyte-like cells lacked 33D1 determinants both by immunofluorescence (Fig. 1, group 3) and by antibody-mediated cytotoxicity (Fig. 1, group 5) . These results indicate that most of the large Ia' cells in islets are related to the 33D1+ dendritic cells previously isolated from lymphoid organs.
Effects of Anti-Dendritic Cell Antibody on Islet Allograft
Survival. The majority (83%) of B6 recipients receiving untreated B1O.BR islets rejected the islets by 12 days after transplantation (Fig. 3, group 1) . These results are comparable to our previous studies (1) and those of Morrow et al. (17) . The small number that failed to reject the allografts may represent animals that received islets with insufficient numbers of passenger cells to induce rejection. Islet allografts treated with rabbit complement alone prior to transplantation were also acutely rejected (Fig. 3, group 2) . Transplants of B10.BR islets treated with monoclonal antimouse dendritic cell reagent (33D1) and complement resulted in allograft survival in eight of the nine recipients for at least 65 days after transplantation (Fig. 3, group 3) . One islet graft was rejected at 12 days. As shown in Fig. 4A , the recipients remained normoglycemic beyond 200 days.
Initiation of Rejection of Established Islet Allografts with Donor Dendritic Cells. Previous studies have demonstrated that the intravenous injection of donor lymphoid cells would induce the acute rejection of established islet allografts in rats (3) and mice (1). For example, at 100 days after transplantation, established mouse islet allografts are rejected by two injections of 1 x 107 donor splenocytes.
We studied four mice with established allografts 65 days after transplantation of islets pretreated with anti-dendritic (Fig. 4B) (4, 5, 9, 16 
